• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

    29.73 +0.39 (+1.31%)
    Streaming Delayed Price Updated: 3:57 PM EST, Feb 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 634,565
    Open 29.35
    Bid (Size) 29.71 (700)
    Ask (Size) 29.74 (500)
    Prev. Close 29.34
    Today's Range 28.65 - 29.88
    52wk Range 12.91 - 42.13
    Shares Outstanding 60,717,176
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Travere Therapeutics (NASDAQ:TVTX) Posts Q4 Earnings Beat on Profitability Despite Revenue Miss ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
    From Travere Therapeutics, Inc.
    Via Business Wire

    Performance

    YTD
    -24.8%
    -24.8%
    1 Month
    -0.7%
    -0.7%
    3 Month
    -18.0%
    -18.0%
    6 Month
    +70.4%
    +70.4%
    1 Year
    +43.9%
    +43.9%

    More News

    Read More
    News headline image
    Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    Why Did TVTX Stock Crash 30% In Pre-Market Today? ↗
    Via Stocktwits
    Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Technical and Fundamental Momentum for Growth Investors ↗
    Via Chartmill
    News headline image
    Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
    Via The Motley Fool
    News headline image
    Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
    Via The Motley Fool
    News headline image
    Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
    From Travere Therapeutics, Inc.
    Via Business Wire
    News headline image
    Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Travere Therapeutics, Inc.
    Via Business Wire
    News headline image
    Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
    From Travere Therapeutics, Inc.
    Via Business Wire
    News headline image
    Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗
    Via The Motley Fool
    News headline image
    Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? ↗
    Via The Motley Fool
    News headline image
    TVTX INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Travere Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm
    From Robbins Geller Rudman & Dowd LLP
    Via Business Wire
    News headline image
    Why Travere Therapeutics Stock Got Trounced on Tuesday ↗
    Via The Motley Fool
    News headline image
    Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS
    Via MarketMinute
    News headline image
    Travere Therapeutics Stock Slumps After FDA Extends Drug Review Timeline To April ↗
    Via Stocktwits
    News headline image
    Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS
    From Travere Therapeutics, Inc.
    Via Business Wire
    Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
    Via Chartmill
    These stocks are gapping in today's session ↗
    Via Chartmill
    These stocks that are showing activity before the opening bell on Tuesday. ↗
    Via Chartmill
    News headline image
    Travere Therapeutics Provides Corporate Update and 2026 Outlook
    From Travere Therapeutics, Inc.
    Via Business Wire
    News headline image
    Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Travere Therapeutics, Inc.
    Via Business Wire
    News headline image
    Why Travere Therapeutics Stock Popped by Nearly 14% on Wednesday ↗
    Via The Motley Fool
    News headline image
    Travere Therapeutics Inc (NASDAQ:TVTX) Shows Strong Momentum and Technical Setup for Growth Investors ↗
    Via Chartmill

    Frequently Asked Questions

    Is Travere Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Travere Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Travere Therapeutics, Inc. - Common Stock trade on?
    Travere Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Travere Therapeutics, Inc. - Common Stock?
    The ticker symbol for Travere Therapeutics, Inc. - Common Stock is TVTX on the Nasdaq Stock Market
    What is the current price of Travere Therapeutics, Inc. - Common Stock?
    The current price of Travere Therapeutics, Inc. - Common Stock is 29.73
    When was Travere Therapeutics, Inc. - Common Stock last traded?
    The last trade of Travere Therapeutics, Inc. - Common Stock was at 02/26/26 03:57 PM ET
    What is the market capitalization of Travere Therapeutics, Inc. - Common Stock?
    The market capitalization of Travere Therapeutics, Inc. - Common Stock is 1.80B
    How many shares of Travere Therapeutics, Inc. - Common Stock are outstanding?
    Travere Therapeutics, Inc. - Common Stock has 2B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.